符合肝细胞癌监测指南与代偿期病毒性肝硬化患者经提前时间校正后生存率提高相关:一项多中心队列研究
基于法国35个中心的前瞻性ANRS CO12 CirVir队列,纳入216例随访期间发生肝细胞癌的活检证实病毒性肝硬化患者。符合监测指南(末次影像与诊断间隔少于7个月)者129例(60.0%),校正提前时间后中位总生存53.2个月,非符合者25.4个月(P=.0107)。多因素分析中符合指南与更低肿瘤负荷、接受根治性治疗及更长总生存相关(HR 2.19,95%CI 1.16-4.14,P=.0150)。
要点
- 符合监测指南者中位总生存53.2个月,非符合者25.4个月(P=.0107)。
- 多因素分析符合指南与总生存改善相关(HR 2.19,95%CI 1.16-4.14)。
- 符合指南与早期诊断和接受根治性治疗相关。
核心结论
- 在ANRS CO12 CirVir队列分析中,符合肝细胞癌监测指南(影像评估间隔少于7个月)与丙型肝炎病毒或乙型肝炎病毒相关代偿期肝硬化且诊断为肝细胞癌患者的早期诊断、接受根治性治疗及经校正后更长的总生存相关。
研究设计与样本
- 前瞻性ANRS CO12 CirVir研究,收集2006年3月至2012年6月法国35个中心1671例活检证实病毒性肝硬化且无既往肝脏并发症、正在接受肝细胞癌监测的患者。
- 仅纳入随访期间发生肝细胞癌的216例患者进行分析;末次监测影像评估与肝细胞癌诊断间隔少于7个月为符合监测指南,7个月及以上为不符合。
主要发现
- 216例患者中位随访59.7个月时检出肝细胞癌,140例(80.5%)为巴塞罗那临床肝癌分期0/A期,135例(69.9%)接受一线根治性治疗(15例移植、29例切除、89例经皮消融、2例切除联合经皮消融),129例(60.0%)符合监测指南。
- 肝细胞癌患者中79例死亡,其中49例死亡与肿瘤进展相关。
- 校正提前时间后,符合监测指南者中位总生存53.2个月,长于不符合者的25.4个月(P=.0107);改变提前时间假设后该差异仍显著。
- 校正倾向评分的多因素分析中,与不符合监测指南相比,符合监测指南与低肿瘤负荷、接受根治性治疗及总生存延长相关(总生存的风险比为2.19,95%CI 1.16-4.14,P=.0150)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Semi-annual surveillance for hepatocellular carcinoma (HCC) is recommended for patients with cirrhosis. We aimed to determine how compliance with HCC surveillance guidelines affects survival times of patients with hepatitis C virus- or hepatitis B virus-associated compensated cirrhosis who developed HCC. METHODS: We collected data from the prospective ANRS CO12 CirVir study, from March 2006 through June 2012, on 1671 patients with biopsy-proven viral cirrhosis and no previous liver complications who were undergoing surveillance for HCC at 35 centers in France. Only 216 patients who developed HCC during the follow-up period were included in the analysis. Patients were considered to be compliant with surveillance guidelines if the time between their last surveillance image evaluation and diagnosis of HCC were fewer than 7 months and noncompliant if this time was 7 months or longer. RESULTS: HCC was detected in 216 patients, at a median follow-up time of 59.7 months. Of these patients, 140 (80.5%) were Barcelona Clinic Liver Cancer stage 0/A, 135 (69.9%) received first-line curative treatment (15 underwent transplantation, 29 underwent resection, 89 received percutaneous ablation, and 2 received resection and percutaneous ablation), and 129 (60.0%) were compliant with surveillance guidelines. Seventy-nine of the patients with HCC died; 49 deaths were associated with tumor progression. After lead-time adjustment, overall survival (OS) time was longer in patients compliant with surveillance guidelines (median OS time, 53.2 months) than noncompliant patients (median OS time, 25.4 months) (P = .0107); this difference remained significant even when we changed lead time assumptions. In multivariate analysis adjusted for a propensity score, compliance with HCC surveillance guidelines was associated with low tumor burden, allocation of curative treatment, and increased OS time compared with noncompliance (hazard ratio for OS, 2.19; 95% confidence interval, 1.16-4.14; P = .0150). CONCLUSIONS: In an analysis of data from the ANRS CO12 CirVir cohort, we associated compliance with HCC surveillance guidelines (fewer than 7 months between image evaluations) with early diagnosis, allocation of curative treatment, and longer adjusted OS of patients with hepatitis C virus- or hepatitis B virus-associated compensated cirrhosis and a diagnosis of HCC.
引用
- Costentin CE, Layese R, Bourcier V, et al. Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study. Gastroenterology. 2018. PMID: 29729258. doi:10.1053/j.gastro.2018.04.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。